Sutro Biopharma reported full‑year revenue of $102.5 million, a 65% increase from $62.0 million in 2024. The jump was driven largely by collaboration revenue from Astellas and Ipsen, and a one‑time gain of $53.2 million reported from the termination of its licensing agreement with Ipsen. The gain, while not fully corroborated at the exact figure in all sources, is the figure the company disclosed and represents a significant one‑off contribution to the year’s top line.
Cash and liquidity were strong at the end of 2025, with cash, cash equivalents and marketable securities totaling $141.4 million on December 31, 2025, down from $167.6 million at the end of September. A $110 million equity raise, priced at $13.98 per share for 7,868,383 shares, extended the company’s runway into the second quarter of 2028, giving management a comfortable buffer to fund ongoing research and development.
Operating expenses fell sharply, with research and development and general & administrative costs dropping from $300.5 million in 2024 to $207.4 million in 2025. The reduction reflects a disciplined cost‑control program that included a third‑of‑staff layoff in September and a shift to external contract manufacturing, which is expected to lower long‑term production costs and free up capital for pipeline development.
The company’s pipeline continued to advance. Phase 1 dosing for STRO‑004 was completed in three cohorts, and the company plans IND submissions for STRO‑006 and STRO‑227 in 2026. Astellas collaboration programs entered the clinic, with a $10 million milestone payment expected in Q2 2026 and a $7.5 million milestone in Q4 2025. Astellas also announced that preclinical results for its TROP2‑targeted iADC program would be presented at AACR in April 2026.
Ipsen’s termination of the STRO‑003 licensing agreement in August 2025 was a notable event, but Sutro stated the termination would not affect its cash runway. The company also announced a strategic shift to contract manufacturing organizations and the planned exit of its San Carlos facility in 2026, further supporting its cost‑control and cash‑generation strategy.
Management expressed confidence in the company’s trajectory. CEO Jane Chung said, "2026 is poised to be a pivotal year, propelled by disciplined clinical execution and initial data that we believe will showcase the vast potential of our proprietary ADC platform." The company’s earnings per share were a loss of $22.49, missing analysts’ expectation of a $17.81 loss, a miss largely attributable to the one‑time termination gain and the high level of operating expenses. Despite the miss, the company’s cash position and pipeline progress reinforce its long‑term growth prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.